Comparing electroCore (ECOR) & Its Competitors

electroCore (NASDAQ:ECOR) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare electroCore to similar businesses based on the strength of its dividends, analyst recommendations, profitability, institutional ownership, earnings, risk and valuation.

Analyst Ratings

This is a summary of current ratings and price targets for electroCore and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1	1	1	0	2.00
electroCore Competitors	4309	10596	18377	837	2.46

electroCore currently has a consensus price target of $18.00, suggesting a potential upside of 242.86%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.20%. Given electroCore’s higher possible upside, research analysts clearly believe electroCore is more favorable than its rivals.

Earnings and Valuation

This table compares electroCore and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
electroCore	$37.97 million	-$13.97 million	-3.78
electroCore Competitors	$1.89 billion	$136.85 million	6.01

electroCore’s rivals have higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

26.7% of electroCore shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 7.8% of electroCore shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares electroCore and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
electroCore	-33.46%	N/A	-74.21%
electroCore Competitors	-300.62%	-179.55%	-22.71%

Volatility and Risk

electroCore has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, electroCore’s rivals have a beta of 5.41, indicating that their average stock price is 441% more volatile than the S&P 500.

Summary

electroCore rivals beat electroCore on 10 of the 13 factors compared.

electroCore Company Profile

electroCore is a medical technology company that develops non-invasive bioelectronic therapies. Its products use non-invasive vagus nerve stimulation (nVNS), which delivers gentle electrical stimulation through the skin to activate the vagus nerve. The company’s gammaCore device is used for the treatment of certain headache conditions, including migraine and cluster headache, subject to its regulatory clearances and indications. electroCore also offers Truvaga, a consumer wellness product that uses non-invasive vagus nerve stimulation.